Novartis revenue increased from $47.4 billion in 2019 to $48.7 billion in 2020, a (2.6%) increase.
Annual Revenue ($)
Novartis revenue was $48.66 b in FY, 2020 which is a (2.6%) year over year increase from the previous period.
Quarterly Revenue ($)
Annual Growth Rate (%)
Revenue Breakdown
Business Segment
Geographic Segment
Novartis revenue breakdown by business segment: 19.8% from Sandoz and 80.2% from Innovative Medicines
Novartis revenue breakdown by geographic segment: 5.3% from China, 5.8% from Japan , 33.9% from United States, 5.0% from France, 9.3% from Germany and 40.8% from Other
| FY, 2020 | FY, 2018 | FY, 2019 | |
|---|---|---|---|
| Sandoz | $9.65 b | $10.04 b | $9.73 b |
| Innovative Medicines | $39.01 b | $35.63 b | $37.71 b |
| Alcon | $7.15 b |
| FY, 2020 | FY, 2018 | FY, 2019 | |
|---|---|---|---|
| Japan | $2.8 b | $3.17 b | $2.66 b |
| Switzerland | $800 m | $852 m | $848 m |
| United States | $16.48 b | $17.56 b | $16.28 b |
| Other | $19.04 b | $22.17 b | $21.1 b |
| France | $2.44 b | $2.71 b | $2.44 b |
| Germany | $4.52 b | $4.18 b | $4.12 b |
| United Kingdom | $1.26 b | ||
| China | 2.57 b |
Need Data?
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.